Rafael Holdings announced that its Phase 3 trial for a Niemann-Pick Disease Type C treatment did not meet the primary endpoint, causing its stock to fall nearly 35%. This led to an investigation by Pomerantz LLP into potential securities fraud or unlawful practices by Rafael and its executives. Investors affected by the stock drop are encouraged to contact the law firm for possible class action participation. The outcome of this investigation could impact Rafael's future operations and investor confidence.
Rafael Holdings' stock fell nearly 35% following a failed Phase 3 trial, prompting an investigation by Pomerantz Law Firm. For readers following the health sector, here is Pluang's market snapshot as of Oct 08, 2026 21:12 WIB: out of 128 priced US health stocks, 17 rose and 111 fell. Notable movers include RXRX at USD 3.96 with a 7.26% drop and 95% sell order activity, BRKR at USD 56.96 down 4.62%, and SMMT at USD 17.12 down 4.60% with 98% buy order activity and a typical hold time of 16 days on Pluang.
Pacira BioSciences was downgraded from Buy to Hold by Needham following Viatris's announcement to acquire the company for $36.50 per share, valuing it at about $1.65 billion. The deal is expected to close by late 2026 and will enhance Viatris's portf...
Seaport Global increased Shopify's price target from $175 to $180, reflecting an 8.3% upside from the current price of $166.16. Shopify's shares have surged 80% since May, pushing its market value above $205 billion. The rally is driven by a strategi...
Tesco reported earnings per share of $0.69, beating estimates of $0.64, despite revenue falling short at $44.60 billion versus $49.60 billion expected. The UK supermarket raised its full-year adjusted operating profit forecast to £3.15-3.30 billion, ...
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
